Subsequent CAR22 infusion was followed by clonal expansion and competition of multiple TP53 gene mutations until a LOH event led to rapid progression into aggressive MDS (Figure 3F, right panel). This evidence concerns the gene TP53 and myelodysplastic syndrome.